Rigel Pharmaceuticals
RIGL
131 hedge funds and large institutions have $447M invested in Rigel Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 58 increasing their positions, 20 reducing their positions, and 15 closing their positions.
190% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 20
100% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 15
12% more funds holding
Funds holding: 117 → 131 (+14)
6% more call options, than puts
Call options by funds: $831K | Put options by funds: $782K
0.25% more ownership
Funds ownership: 9.41% → 9.65% (+0.25%)
9% less capital invested
Capital invested by funds: $490M → $447M (-$43.5M)
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$10.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$10.7M |
| 3 |
TA
Tamarack Advisers
Carlsbad,
California
|
+$9.34M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.71M |
| 5 |
BlackRock
New York
|
+$8.23M |
Top Sellers
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$18.4M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$10M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$5.26M |
| 4 |
JGC
J. Goldman & Co
New York
|
-$2.95M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$2.72M |
RIGL Hedge Fund Activity: Q2 2018 in Review
131 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2018, worth a combined $447M — down 8.9% from $490M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new RIGL positions and 15 closed out — a net gain of 15 holders — while 58 added to existing stakes and 20 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $10.7M. The largest seller was Great Point Partners, cutting an estimated $18.4M.
- 131 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2018, up from 117 in Q1 2018.
- Funds reported $447M of Rigel Pharmaceuticals stock for Q2 2018, down 8.9% quarter-over-quarter.
- 30 funds opened new Rigel Pharmaceuticals positions in Q2 2018 and 15 closed out, a net change of +15 holders.
- The largest Rigel Pharmaceuticals buyer in Q2 2018 was Citadel Advisors, an estimated $10.7M added.
- The largest Rigel Pharmaceuticals seller in Q2 2018 was Great Point Partners, an estimated $18.4M sold.
Based on aggregated 13F filings for Q2 2018.